Piper Sandler analyst David Westenberg maintained a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $80.00. The company’s shares closed last Friday at $53.51.
According to TipRanks, Westenberg is a 2-star analyst with an average return of -0.3% and a 42.07% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Exact Sciences, Myriad Genetics, and Zoetis.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $88.08, implying a 64.60% upside from current levels. In a report released on May 9, Bank of America Securities also reiterated a Buy rating on the stock with a $88.00 price target.
EXAS market cap is currently $9.87B and has a P/E ratio of -40.40.
Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXAS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- Exact Sciences price target lowered to $80 from $85 at BTIG
- Exact Sciences price target lowered to $80 from $100 at Citi
- Exact Sciences price target lowered to $85 from $90 at Canaccord
- Exact Sciences backs FY24 revenue view of $2.81B-$2.85B, consensus $2.83B
- Exact Sciences reports Q1 EPS (60c), consensus (47c)
